Maureen M Okam
Biographic Data
| ID | 5545867 |
|---|---|
| NAME | Maureen M Okam |
| GIVEN NAMES | Maureen M |
| FAMILY NAME | Okam |
| SIGNATURE | OKAM M M |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2014 |
| LATEST PUBLICATION YEAR | 2014 |
| H-INDEX | 0 |
National Trends in Hospitalizations for Sickle Cell Disease in the United States Following the FDA Approval of Hydroxyurea, 1998–2008
BACKGROUND: Patients with sickle cell disease (SCD) can suffer frequent hospital admissions for painful vasoocclusive crises. Hydroxyurea was approved by the FDA in 1998 to decrease the morbidity of SCD, but nationwide hospitalizations for SCD in the United States since 1998 have not been evaluated. We hypothesized that the availability of hydroxyurea for SCD would be associated with a decrease in hospitalizations for SCD over time. OBJECTIVE: To…
No prominent works on this page.
National Trends in Hospitalizations for Sickle Cell Disease in the United States Following the FDA Approval of Hydroxyurea, 1998–2008
BACKGROUND: Patients with sickle cell disease (SCD) can suffer frequent hospital admissions for painful vasoocclusive crises. Hydroxyurea was approved by the FDA in 1998 to decrease the morbidity of SCD, but nationwide hospitalizations for SCD in the United States since 1998 have not been evaluated. We hypothesized that the availability of hydroxyurea for SCD would be associated with a decrease in hospitalizations for SCD over time. OBJECTIVE: To…
Blood groups and transfusion (1 work) · Cohort study (1 work) · Confidence interval (1 work) · Disease (1 work) · Emergency Medicine (1 work) · Emergency Medicine (1 work) · Environmental health (1 work) · Hemoglobinopathies and Related Disorders (1 work) · Internal Medicine (1 work) · Internal Medicine (1 work)